Clinical trials: Aripiprazole
Hyperprolactinemia, Weight Gain
Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia
This is a prospective, open-label study to evaluate the efficacy and safety in reducing antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole.
- Conditions
- Hyperprolactinemia, Weight Gain, Dyslipidemia
- Trial name
- NCT00541554
- Testing
- Abilify (aripiprazole)
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Schizophrenia, Tardive Dyskinesia, Metabolic Syndrome
The Monitor of Serum Prolactin Level in a 3 Months Aripiprazole Trial
A short term post-market monitoring of serum prolactin level change among patients with schizophrenia shifting from other antispychotics to different dosages of aripiprazole.
- Trial name
- NCT00468533
- Testing
- Aripiprazole
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Yu-Li Hospital